Phase 2 N=253 Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Feasibility Study of a Novel Device for Chronic Wounds
Ulcer · Wounds and Injuries
Primary: Ease of Use for Patients — 8; 10; 9 participants
Phase 3 N=557 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.81; -1.13 Percentage (%) — p=< 0.001
N/A N=20 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Functional Recovery — 10; 1; 6; 3 Participants
N/A N=34 Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)
Exocrine Pancreatic Insufficiency
Primary: Number of Patients With Adverse Events and Unanticipated Adverse Device Effects — 4; 6; 1; 2 Participants
Phase 2 N=75 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Lung Cancer
Primary: Overall Survival at 12 Months — 57 percentage of participants
Phase 2 N=106 A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12) — 70.6; 100; 93.8 percentage of participants
Phase 1 N=20 A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma
Asthma
Primary: Time to Reach Maximum Observed Serum Concentration (Tmax) — 5.2; 6.1 days
Phase 1 N=80 First in Man Trial of BI 113608
Healthy
Primary: Clinically Relevant Abnormalities for Clinical Laboratory Evaluation, Vital Signs, Lung Function, Carbon Monoxide Diffusing Capacity of the Lung, ECG, Physical…
Phase 1 N=97 Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers
Healthy
Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants
N/A N=20 Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
Ovarian Failure, Premature
Primary: Estradiol — 53; 14; 12 pg/mL
N/A N=150 IV Iron for the Anemia of Traumatic Critical Illness
Trauma · ICU Anemia
Primary: RBC Transfusion — 47; 55 participants
N/A N=30 Oral Peanut Immunotherapy
Peanut Allergy
Primary: Tolerance or Sustained Unresponsiveness — 2; 7 Participants
N/A N=51 NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock
SIRS · Sepsis · Shock
Primary: Pattern of NT-proBNP, Biomarkers and Surface Markers on Leukocytes — 902; 4,429 pg/ml
Phase 2 N=53 Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Growth Hormone Deficiency (GHD)
Primary: Incidence of Anti-hGH Binding Antibody Formation — 1; 0; 0; 0 participants